Verovaccines utilizes a recombinant yeast platform based on _Kluyveromyces lactis_ to rapidly develop and optimize subunit vaccines for animals. This technology accelerates the vaccine registration process, addressing the need for efficient and effective animal health solutions.
Funding
Funding not disclosed
Founders
Product
Problem
The animal vaccine development process is often slow and inefficient, hindering the rapid response to emerging disease threats and limiting the availability of effective animal health solutions. Traditional vaccine production methods can be cumbersome and time-consuming.
Solution
Verovaccines has developed a recombinant yeast platform based on _Kluyveromyces lactis_ for the rapid development and optimization of subunit vaccines for animals. This platform enables the efficient expression of one or more antigens, accelerating the vaccine registration process. The technology offers advantages throughout the entire value chain, from vaccine design to commercialization, allowing for a faster track to novel animal vaccines. By leveraging this platform, Verovaccines aims to provide innovative and effective animal health solutions to address the evolving needs of the industry.
Target Audience
The primary target audience includes animal health companies, veterinary vaccine manufacturers, and research institutions focused on developing and improving animal vaccines.
Features
- Recombinant _Kluyveromyces lactis_ yeast platform for antigen expression.
- Rapid vaccine development and optimization.
- Efficient subunit vaccine production.
- Accelerated vaccine registration process.